

LETTERS TO THE EDITOR

Considerations for Statin Therapy in Patients with COVID-19

Simin Dashti-Khavidaki  and Hossein Khalili* 

Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

(Pharmacotherapy 2020;40(5):484–486) doi: 10.1002/phar.2397

The current coronavirus pandemic is an outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the third coronavirus outbreak during the current century, after the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses.¹

Acute respiratory distress syndrome (ARDS) is an immunopathologic event and the main cause of death following COVID-19. The main mechanism of ARDS is uncontrolled systemic inflammatory response and cytokine storm following the release of proinflammatory cytokines (e.g., interferons [IFNs], interleukins [ILs], tumor necrosis factor [TNF]- α) and chemokines.^{2, 3} Therefore, some Chinese researchers proposed or used anti-inflammatory agents in the treatment regimen of patients with COVID-19.^{3, 4}

Statins are well known for their anti-inflammatory effects,⁵ and some hospitals included them in the COVID-19 treatment protocol.⁶ Here, we summarize the main points that should be considered before incorporating this class of drugs in a COVID-19 treatment regimen.

Potential Mechanistic Effects/Adverse Effects of Statins on ARDS

Toll-like receptors (TLRs), a family of sensor proteins, assist the immune system to

discriminate between “self” and “non-self.” In a mice model, researchers demonstrated that TLR signaling through TRIF adaptor protein mitigate ARDS as a main cause of death in SARS-CoV disease.⁷ Gene expression of myeloid differentiation primary response 88 (*MyD88*) acts downstream of TLRs and is induced by SARS-CoV infection.⁷ Both overexpression⁷ and underexpression of *MyD88* gene⁸ were related to increased mortality after MERS-CoV infection. Downstream of TLRs-MyD88 pathways, NF- κ B is activated by coronavirus infections. In a mice model, inhibition of NF- κ B improved lung infection and survival after SARS-CoV infection.⁹ Statins preserve *MyD88* at normal levels during hypoxia¹⁰ and mitigate NF- κ B activation,¹¹ so some investigators hypothesized the idea of using statins for the treatment of MERS-CoV infection¹² and COVID-19.¹³ But animal studies have shown that aberrant inhibition of TLR adaptor TRIF or *MyD88* signals results in severe lung damage and death.^{7, 14} This may be due to the compensatory activation of other innate immune factors. In addition, animal studies on SARS-CoV and MERS-CoV infections revealed that abolished TLR pathway leads to increased viral load that persists for a longer time and increases the risk of human-to-human transmission.^{7, 14} Therefore, statins, by the potential to stop TLR and NF- κ B signaling, carry the potential risk of exacerbating compensatory immune signals and poor disease outcome. Although some human and animal studies have shown lung injury improvement of statins via their anti-inflammatory effects,^{15, 16} a retrospective analysis of the findings of a multicenter clinical trial on the efficacy of rosuvastatin against infection-induced ARDS showed higher IL-18 level

Conflict of interest: The authors declare no conflicts of interest.

*Address for correspondence: Hossein Khalili, Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, P.O. Box: 1417614411, Tehran, Iran; e-mail: khalilih@sina.tums.ac.ir.

© 2020 Pharmacotherapy Publications, Inc.

and mortality in statin-treated patients.¹⁷ The findings on the effects of statin on community-acquired¹⁸ and ventilator-associated pneumonia^{19, 20} are conflicting as well.

Finally, for the COVID-19 outbreak, although some US hospitals included statins in COVID-19 treatment⁶ and some proposed their use for this condition,¹³ some others worry regarding statin-induced increase in IL-18 and deterioration of SARS-CoV-2-induced ARDS and mortality.²¹

Considerations in Real Situation

We have to notice that patients with common comorbidities, including hypertension, cardiovascular diseases, and diabetes, are at greater risk for SARS-CoV-2 infection and its related ARDS and mortality.²² Most of these patients are taking statins routinely based on diabetes and cardiovascular guidelines. There is no evidence for discontinuing statins in these patients during the COVID-19 episode.

Common Adverse Effects Between COVID-19 and Statins

Although usually well tolerated, statins may cause myotoxicity in some patients. Features of statin-induced myotoxicity differ from those of myalgia (more common) to myopathies and rarely rhabdomyolysis. Rhabdomyolysis can cause acute kidney injury.²³ Myalgia, increased creatine phosphokinase, rhabdomyolysis, and acute kidney injury occur in patients with COVID-19 as well.² In addition, some risk factors such as advanced age and liver and kidney impairments are common between statin-induced myopathies and infection with SARS-CoV-2.^{2, 23} Thus, initiating statins in patients with COVID-19 may increase the risk and severity of myopathies and acute kidney injury. Furthermore, statin therapy and COVID-19 both increase liver enzymes that are hard to differentiate from each other, if statin therapy starts at the episode of COVID-19.²

Drug Interaction Between Statins and Antiviral Agents for COVID-19 Treatment

Most available statins are substrate for the cytochrome P450 (CYP) system, especially 3A isoenzymes and P-glycoproteins (P-gp). Protease inhibitors (e.g., lopinavir, darunavir) and their pharmacokinetic enhancers (ritonavir and cobicistat) are potent inhibitors of both CYP3A

and P-gp, and their concomitant administration results in markedly increased statin exposure and adverse effects. Coadministration of simvastatin or lovastatin with ritonavir/cobicistat-boosted protease inhibitors should be avoided. Maximum daily doses of 20 mg for atorvastatin and 10–20 mg for rosuvastatin have been proposed in patients receiving ritonavir/cobicistat-boosted protease inhibitors.^{24, 25}

Conclusion

Taken together, although there is an urgent need for finding safe and available options for treatment of COVID-19 and its related fatal ARDS, we must balance our expectation from these immunomodulatory drugs against the potential of disease exacerbation by these agents.

We recommend guideline-directed continuation of statin therapy among COVID-19 patients with a history of atherosclerotic cardiovascular disease or diabetes. We recommend guidance-directed initiation of statin in patients with COVID-19 who show acute cardiac injury. But, de novo initiation of statin therapy for management of COVID-19 episode can be done only as a clinical trial, not routinely.

References

1. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. *J Pharm Anal* 2020. <https://doi.org/10.1016/j.jppha.2020.03.001>
2. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020. <https://doi.org/10.1056/NEJMoa2002032>
3. Conti P, Ronconi G, Caraffa A, et al. Induction of proinflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents* 2020;34(2). <https://doi.org/10.23812/CONTI-E>
4. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of immunologists from China. *Clin Immunol* 2020. <https://doi.org/10.1016/j.clim.2020.108393>
5. Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? *Circulation* 2004;109(21_suppl_1):II-18–II-26.
6. Massachusetts General Hospital COVID-19 Treatment Guidance Version 1.0 3/17/2020. Available at: <https://medtube.net/infectious-diseases/medical-documents/26086-covid19-treatment-guidelines-by-massachusetts-general-hospital>. Accessed March 28, 2020.
7. Totura AL, Whitmore A, Agnlhram S, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. *mBio* 2015;6(3):e00638–15.
8. Sheahan T, Morrison TE, Funkhouser W, et al. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. *PLoS Pathog* 2008;4:e1000240.
9. DeDiego ML, Nieto-Torres JL, Regla-Nava JA, et al. Inhibition of NF-κB-mediated inflammation in severe acute respiratory

- syndrome coronavirus-infected mice increase survival. *J Virol* 2014;88:915–24.
10. Yuan X, Deng Y, Guo X, Shang J, Zhu D, Li H. Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: partly involvement of TLR4/MyD88 pathway. *Biochem Biophys Res Commun* 2014;446:292–7.
 11. Chansrichavala P, Chantharaksri U, Sritara P, Chaiyaroj SC. Atorvastatin attenuates TLR-4-mediated NF-kappa B activation in a MyD88-dependent pathway. *Asian Pac J Allergy Immunol* 2009;27:49–57.
 12. Yuan S. Statins may decrease the fatality rate of Middle East respiratory syndrome infection. *mBio* 2015;6(4):e01120–15.
 13. Fedson DS, Opal SM, Rordamc OM. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. *mBio* 2020;11(2):e00398–20.
 14. Totura AL, Baric RS. Reply to “statins may decrease fatality rate of MERS infection. *mBio* 2015;6(5):e01303–15.
 15. Shyamsundar M, McKeown STW, O’Kane CM, et al. Simvastatin decreases lipopoly-saccharide-induced pulmonary inflammation in healthy volunteers. *Am J Respir Crit Care Med* 2009;179:1107–14.
 16. Chen W, Sharma R, Rizzo AN, Siegler JH, Garcia JG, Jacobson JR. Role of claudin-5 in the attenuation of murine acute lung injury by simvastatin. *Am J Respir Cell Mol Biol* 2014;50:328–36.
 17. Rogers A, Guan J, Trtchounian A, et al. Association of elevated plasma interleukin-18 level with increased mortality in a clinical trial of statin treatment for acute respiratory distress syndrome. *Crit Care Med* 2019;47:1089–96.
 18. Garnacho-Montero J, Barrero-García I, Gómez-Prieto MG, Martín-Loeches I. Severe community-acquired pneumonia: current management and future therapeutic alternatives. *Expert Rev Anti Infect Ther* 2018;16(9):667–77.
 19. Makris D, Manoulakas E, Komnos A, et al. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. *Crit Care Med* 2011;39(11):2440–6.
 20. Papazian L, Roch A, Charles PE, et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. *JAMA* 2013;310(6):1692–700.
 21. Goldstein MR, Graeber CW, Poland GA. Are certain drugs associated with enhanced mortality in COVID-19. *QJM* 2020. <https://doi.org/10.1093/qjmed/hcaa103>
 22. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020. <https://doi.org/10.1001/jamainternmed.2020.0994>
 23. Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomics and muscle components. *J Clin Med* 2020. <https://doi.org/10.3390/jcm9010022>
 24. Liverpool COVID-19 drug interactions. <http://www.covid19-druginteractions.org/>. Accessed March 20, 2020.
 25. Lexicomp Mobile apps. Hudson, Ohio, Wolters Kluwer Clinical Drug Information, Inc., 4 March 2020.